Back to search
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This is a first-in-human, open-label, single ascending dose study of TTX-381 for the treatment of ocular manifestations of CLN2 (Batten disease).
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, i…
This is a multicenter, observational study for patients with a confirmed diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as TPP1 d…
The goal of this clinical trial is to learn if a gene therapy called scAAV9.CB.CLN6 can treat children with CLN6 Batten disease (variant late infantile neuronal…